European Journal of Cancer最新文献

{"title":"Letter Re: Evaluation of screening mammography effectiveness: The IARC recommendations of 2015 need revision","authors":"Paolo Giorgi Rossi, Francesco Venturelli","doi":"10.1016/j.ejca.2025.115659","DOIUrl":"10.1016/j.ejca.2025.115659","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"227 ","pages":"Article 115659"},"PeriodicalIF":7.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144694850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of screening mammography effectiveness: The IARC recommendations of 2015 need revision","authors":"Philippe Autier ,&nbsp;Karsten Juhl Jørgensen ,&nbsp;Henrik Støvring","doi":"10.1016/j.ejca.2025.115657","DOIUrl":"10.1016/j.ejca.2025.115657","url":null,"abstract":"<div><div>Breast cancer screening effectiveness is measured by its ability to reduce breast cancer mortality in real world settings. A viewpoint issued by the International Agency for Research on Cancer (IARC) in 2015 considered that observational studies (cohort and case-control) are the preferred methods to evaluate the effectiveness of mammography screening. A statistical method was deemed to correct for differences in personal characteristics between women choosing to attend or to not attend screening (self-selection bias). But we showed in a systematic review of observational studies that, compared to women who never attend screening, attenders have a 45 % reduction in their risk of breast cancer death (95 % CI: 40–50 %) and a 46 % reduction (95 % CI: 42–50 %) in their risk of death from a cause other than breast cancer. Screening mammography has no known beneficial influence on causes of death other than breast cancer. If screening mammography reduced the risk of breast cancer death, one would expect a much greater percentage reduction in the risk of breast cancer death than in the risk of all-cause death. Our results suggest that screening mammography attendance is an indicator of personal characteristics associated with a lower risk of dying from any cause, including from breast cancer, which observational studies have misinterpreted as a screening effect. This paper calls into question the IARC 2015 recommendations and advocates the reinstatement of recommendations made by the IARC in 2002 which were based on the use of descriptive and comparative studies.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"227 ","pages":"Article 115657"},"PeriodicalIF":7.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144694847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the current perspective: Evaluation of screening mammography effectiveness: The IARC recommendations of 2015 need revision","authors":"Beatrice Lauby-Secretan","doi":"10.1016/j.ejca.2025.115658","DOIUrl":"10.1016/j.ejca.2025.115658","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"226 ","pages":"Article 115658"},"PeriodicalIF":7.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma","authors":"Mees D. Egeler ,&nbsp;Sebastian Klobuch ,&nbsp;Willemijn S. Tak ,&nbsp;Maartje W. Rohaan ,&nbsp;Troels H. Borch ,&nbsp;Inge. M. Noringriis ,&nbsp;Renaud Tissier ,&nbsp;Minke W. Lucas ,&nbsp;Winan van Houdt ,&nbsp;Alexander C.J. van Akkooi ,&nbsp;Inge Jedema ,&nbsp;Marco Donia ,&nbsp;Christian U. Blank ,&nbsp;Inge Marie Svane ,&nbsp;John B.A.G. Haanen ,&nbsp;Lonneke V. van de Poll-Franse","doi":"10.1016/j.ejca.2025.115640","DOIUrl":"10.1016/j.ejca.2025.115640","url":null,"abstract":"<div><h3>Aims</h3><div>Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has demonstrated benefit for patients with advanced melanoma refractory to first-line immune checkpoint inhibitors (ICIs). However, predictive biomarkers for TIL therapy response are limited. Preclinical studies suggest that emotional distress (ED) may impair antitumor immune responses. We conducted a post-hoc analysis of the phase III TIL trial (NCT02278887) to evaluate the association between pretreatment ED and TIL therapy outcomes.</div></div><div><h3>Methods</h3><div>ED was evaluated using a composite score derived from the Impact of Event Scale and the emotional functioning subscale of the EORTC QLQ-C15-PAL. Patients were stratified into elevated ED (n = 32) or normal ED (n = 40) groups using a median split approach. To evaluate whether the obtained results were dependent on the ED classification method, a sensitivity analysis was conducted to compare TIL therapy outcomes between patients with composite ED scores in the lowest tertile (normal ED, n = 26) and highest tertile (elevated ED, n = 25).</div></div><div><h3>Results</h3><div>Elevated ED was associated with a reduced objective response rate (37 % vs. 69 %; adjusted odds ratio, 0.28; 95 % confidence interval [CI], 0.19–0.75; P = 0.013) and decreased progression-free survival rates at 1-year (31 % vs. 58 %) and 2-years (16 % vs. 35 %; adjusted hazard ratio, 1.84; 95 % CI, 1.03–3.26; P = 0.038). Sensitivity analysis using the tertile grouping method showed a similar trend (odds ratio, 0.35; 95 % CI, 0.11–1.08, P = 0.072).</div></div><div><h3>Conclusion</h3><div>Our findings suggest that elevated ED before TIL therapy is associated with reduced therapeutic outcomes, underscoring the need for further investigation into the stress-immune-cancer axis.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"227 ","pages":"Article 115640"},"PeriodicalIF":7.6,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144633345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor on “Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76K trial”","authors":"John M. Kirkwood","doi":"10.1016/j.ejca.2025.115636","DOIUrl":"10.1016/j.ejca.2025.115636","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"227 ","pages":"Article 115636"},"PeriodicalIF":7.6,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors","authors":"Claire Gallois ,&nbsp;Margherita Ambrosini ,&nbsp;Sara Lonardi ,&nbsp;Emily Alouani ,&nbsp;Rosine Guimbaud ,&nbsp;Michael J. Overman ,&nbsp;Frank Sinicrope ,&nbsp;Thibault Mazard ,&nbsp;Marie Decraecker ,&nbsp;Javier Ros ,&nbsp;Elena Elez ,&nbsp;Simon Pernot ,&nbsp;Chiara Cremolini ,&nbsp;Alice Boilève ,&nbsp;Pauline Parent ,&nbsp;Priya Jayachandran ,&nbsp;Marie Dutherage ,&nbsp;Mathilde Mercier ,&nbsp;Clémence Flecchia ,&nbsp;Marwan Fakih ,&nbsp;David Tougeron","doi":"10.1016/j.ejca.2025.115645","DOIUrl":"10.1016/j.ejca.2025.115645","url":null,"abstract":"<div><h3>Introduction</h3><div>The prognostic impact of the <em>BRAF</em> V600E mutation in patients with deficient mismatch repair (dMMR)/microsatellite instability (MSI) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI) is poorly understood.</div></div><div><h3>Material and methods</h3><div>This retrospective international study included patients with dMMR/MSI mCRC treated with ICI all lines between 2014 and 2023, and available <em>BRAF</em> mutation status.</div></div><div><h3>Results</h3><div>Of 909 patients included, 345 (38 %) had <em>BRAF</em> V600E dMMR/MSI mCRC. In multivariable analysis, BRAFm was not associated with a shorter progression-free survival (PFS) and overall survival (OS) from ICI start compared to BRAFwt patients (median PFS: 25.0 vs 41.5 months, adjusted hazard ratio (adjHR)= 0.97, p = 0.8 and OS: 55.1 months vs not reached adjHR= 0.98, p = 0.9). However, in patients treated with ICI in first line, the rate of secondary resistance, defined as the progression after the first 6 months of treatment, was higher in BRAFm patients (20 % vs 11 %, p = 0.02). In patients with disease control for 6 months in 1st line, the PFS and OS from this point onwards were significantly shorter in BRAFm patients (adjHR for PFS 2.09, p = 0.03 and adjHR for OS 2.80, p = 0.019). The poor prognostic value of the <em>BRAF</em> mutation was no longer observed in patients treated with anti-PD1 and anti-CTLA4 combination.</div></div><div><h3>Conclusions</h3><div>In patients with dMMR/MSI mCRC, the <em>BRAF</em> V600E mutation is not associated with a shorter PFS/OS on ICI treatment in the overall population across all lines. However, specifically in patients treated in the first-line setting, our results suggest that the <em>BRAF</em> mutation is associated with a higher rate of secondary resistance, suggesting that a combination of PD1 and CTLA4 inhibitors upfront may be of particular interest in these patients.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"227 ","pages":"Article 115645"},"PeriodicalIF":7.6,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144665886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study","authors":"Davide Ciardiello ,&nbsp;Luca Boscolo Bielo ,&nbsp;Stefania Napolitano ,&nbsp;Eleonora Cioli ,&nbsp;Tiziana Pia Latiano ,&nbsp;Alfonso De Stefano ,&nbsp;Emiliano Tamburini ,&nbsp;Matteo Ramundo ,&nbsp;Roberto Bordonaro ,&nbsp;Alessia Erika Russo ,&nbsp;Salvatore Pisconti ,&nbsp;Claudia Nisi ,&nbsp;Claudio Lotesoriere ,&nbsp;Simona Vallarelli ,&nbsp;Sara Lonardi ,&nbsp;Viola Barruca ,&nbsp;Chiara Cremolini ,&nbsp;Giampaolo Tortora ,&nbsp;Pierosandro Tagliaferri ,&nbsp;Filippo Pietrantonio ,&nbsp;Giulia Martini","doi":"10.1016/j.ejca.2025.115642","DOIUrl":"10.1016/j.ejca.2025.115642","url":null,"abstract":"<div><h3>Introduction</h3><div>We investigated the role of integrating tissue biopsy (TBx)- and liquid biopsy (LBx)-comprehensive genomic profiling (CGP) to predict the activity of FOLFIRI plus cetuximab.</div></div><div><h3>Methods</h3><div>The CAPRI-2 GOIM study is a non-randomized phase 2 study evaluating a biomarker-driven anti-EGFR treatment in three lines of therapy in patients with <em>RAS/BRAF</em>^{<em>V600E</em>} wild type metastatic colorectal cancer. At baseline, TBx and LBx were analyzed using the FoundationOne CDx platform. Analysis of overall response rate (ORR) and median progression free survival (mPFS) according to molecular profiles were performed.</div></div><div><h3>Results</h3><div>Overall, 156 patients were evaluable for tumor response and had matched tissue and plasma-based CGP. Negatively hyper-selected patients by both TBx- and LBx-CGP showed higher ORR (79.6 % versus 44.2 %, P &lt; 0.001) and mPFS compared to mutated cases (12.4 months versus 7.4 months, P &lt; 0.001). Eight and 12 cases harbored mutations detected by TBx and LBx-CGP only, respectively. Compared to discordant cases (n = 20), concordant cases (n = 23) showed a trend for lower ORR (39.1 % versus 50.0 %, P = 0.5) and shorter mPFS (3.94 versus 11.50 months, P = 0.02). Patients with alterations detected only by TBx-CGP had significantly lower circulating tumor DNA (ctDNA) tumor fraction (TF) compared to concordant cases (1.7 % versus 23.0 %; P = 0.01). Using a ctDNA TF threshold ≥ 10 % nearly all (19 of 20) TBx detected pathogenic variants (PV) were also identified by LBx-CGP. In eight cases detected by LBx only, mPFS was 8.24 months.</div></div><div><h3>Conclusion</h3><div>In cases with high TF LBx-CGP predicts efficacy of anti-EGFR therapy, while for TF&lt; 10 % TBx-CGP provides additional data on PVs that could affect treatment efficacy.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"226 ","pages":"Article 115642"},"PeriodicalIF":7.6,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients – A post-hoc analysis of the PETACC 8 trial","authors":"Elisabeth Sophie Bergen ,&nbsp;Clémence Canton ,&nbsp;Mathieu Boulin ,&nbsp;Karine Le Malicot ,&nbsp;Jaafar Bennouna ,&nbsp;Daniel Gonzalez ,&nbsp;Laurent Mineur ,&nbsp;Olivier Bouche ,&nbsp;Côme Lepage ,&nbsp;Julien Taieb","doi":"10.1016/j.ejca.2025.115643","DOIUrl":"10.1016/j.ejca.2025.115643","url":null,"abstract":"<div><h3>Background</h3><div>Only few information is available about the impact of concomitant medication (CM) and comorbidities on the outcome of cancer patients and the tolerability of chemotherapy.</div></div><div><h3>Methods</h3><div>Patients of the phase III randomized trial PETACC8 had resection with curative intent of a stage III colon cancer (CC) and were treated with standard adjuvant fluoropyrimidine and oxaliplatin + /- cetuximab over 6 months. Information on CM intake has been gathered by study visits at inclusion as well as during chemotherapy. We investigated the association between number of CM as well as the 5 most frequently applied CM categories according to the WHO ATC classification system (gastro-esophageal reflux disease (GERD) treatment, anticoagulants, platelet aggregation inhibitors, cardiovascular and antidiabetic drugs) with outcome and tolerability.</div></div><div><h3>Results</h3><div>Among 2559 patients, median number of CM intake was 8 (range 0–25), with only 22 patients (0.9 %) without any CM intake. Anticoagulation treatment was the only CM category being significantly and independently associated with a shorter disease-free survival (DFS) (HR 1.29, 95 %CI 1.06–1.56, <em>p = 0.010</em>) as well as overall survival (OS) (HR 1.28, 95 %CI 1.02–1.59, <em>p = 0.032</em>). No association of number of CM (&lt;5,5–10,&gt;10) has been observed neither with DFS (ref.;HR 0.98;HR 1.17) nor OS (ref.;HR 0.98;HR 1.15) (<em>p &gt; 0.05</em>). Patients with anticoagulants experienced significantly more grade 3/4 adverse events (AEs) (75.9 % vs 64.8 %, <em>p = 0.002</em>) and treatment discontinuations due to toxicity (17.7 % vs 10.8 %, <em>p = 0.005</em>) compared to patients without anticoagulants.</div></div><div><h3>Discussion</h3><div>Early CC patients with polypharmacy do not generally exhibit an impaired outcome. Anticoagulation was the only CM category associated with a shorter DFS and OS which might be a consequence of enhanced toxicities necessitating treatment adaptations in these patients.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"227 ","pages":"Article 115643"},"PeriodicalIF":7.6,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial","authors":"Brigit van Dijk,&nbsp;Joséphine C. Janssen,&nbsp;Evalyn E.A.P. Mulder,&nbsp;Karlijn de Joode,&nbsp;Astrid A.M. van der Veldt","doi":"10.1016/j.ejca.2025.115635","DOIUrl":"10.1016/j.ejca.2025.115635","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"227 ","pages":"Article 115635"},"PeriodicalIF":7.6,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful full-dose rechallenge after fruquintinib-associated posterior reversible encephalopathy syndrome","authors":"Georgios Ioannidis,&nbsp;Maria Pittaka,&nbsp;Maro Kleridou,&nbsp;Athena G. Skoulariki,&nbsp;George D. Vavougios","doi":"10.1016/j.ejca.2025.115646","DOIUrl":"10.1016/j.ejca.2025.115646","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"226 ","pages":"Article 115646"},"PeriodicalIF":7.6,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}